Non-peptide

Apitegromab

Also known as

SRK-015 · apitegromab antibody

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A muscle-targeting antibody, also called SRK-015, that blocks activation of myostatin. It is given by IV infusion.
Why people follow it	People with spinal muscular atrophy (SMA) hope for easier movement; biohackers follow research on preserving lean tissue during weight loss.
Muscle target and interest	Myostatin helps limit muscle growth. People with spinal muscular atrophy (SMA) hope for easier movement; biohackers follow research on preserving lean tissue during weight loss.

Notes

Apitegromab is a muscle-targeting antibody, also called SRK-015. SMA communities hope for useful movement gains; biohackers follow its potential to preserve lean tissue during weight loss. Its U.S. prescription form, ISEMBYLD (apitegromab-mstn), was approved for a specific SMA population in September 2026; that does not establish a bodybuilding use.

It blocks a muscle-growth brake before it switches on. Myostatin helps limit muscle growth. Apitegromab binds its inactive precursor forms, preventing activation. This is a manufactured antibody protein given through an IV infusion, rather than an oral supplement or a small peptide for daily under-the-skin injections. Randomized phase 1 study of Apitegromab (2021) (Official context · Accessed 2026-09-30)

Apitegromab is an antibody that blocks myostatin activation. Its U.S. prescription product is approved for a defined spinal muscular atrophy population; other research does not establish a bodybuilding indication.

Helping muscle is different from repairing lost nerves. In an SMA discussion, a commenter hopes for a small noticeable improvement but worries about longstanding damage. Another distinguishes Apitegromab's muscle target from hoped-for nerve treatments. These are expectations, not reports of recovered abilities after taking it. How do you think our future will be like? (Community discussion · Accessed 2026-09-30)

Source context — Randomized phase 1 study of Apitegromab (2021): Healthy adult clinical IV study, not healthy-bodybuilder efficacy or unverified-product kinetics. PMC web page was CAPTCHA; API copy actually read. Blood elimination differs from target response and perceived effects.

Source context — How do you think our future will be like?: Expectations, not Apitegromab treatment results. Four-point claim and approval prediction are not adopted. Relative page timestamps are inconsistent with indexed dates; do not infer a new date from them.

What people notice

Community experience	The saved public SMA accounts express hopes or ask for trial experiences; they do not describe firsthand treatment outcomes.
Lean-tissue trial result	A tirzepatide combination trial reported less lean-mass loss, without notable differences in strength or chair-rise tests.

Notes

Patient hopes are not trial-participant testimonials. The SMA future discussion hopes for modest improvement despite irreversible changes. A different thread asks participants how treatment is going, but its visible respondent is not in the trial and suggests Facebook. These public accounts do not establish positive, unchanged or adverse firsthand Apitegromab experiences. How do you think our future will be like? (Community discussion · Accessed 2026-09-30) · Scholar rock: request for trial experiences (Community discussion · Accessed 2026-09-30)

Keeping lean tissue during a cut drives the GLP-1 interest. A GLP-1 thread highlights EMBRAZE's 1.9 kg smaller lean-mass loss with tirzepatide plus Apitegromab at 24 weeks. Commenters disagree about the value of a better scan when strength and chair-rise tests showed no notable difference. Lean mass includes more than contractile muscle. EMBRAZE lean-mass result versus flat function endpoint (Community discussion · Accessed 2026-09-30) · EMBRAZE: Apitegromab during tirzepatide-induced weight loss (Official context · Accessed 2026-09-30)

Source context — Scholar rock: request for trial experiences: No first-person treatment report in visible reply. No private Facebook access; no universal absence claim.

Source context — EMBRAZE lean-mass result versus flat function endpoint: Trial interpretation, not Apitegromab self-use. Blog and OP are not counted as independent corroboration. Retatrutide anecdote omitted as a treatment outcome for this compound; trial values keep EMBRAZE origin.

Source context — EMBRAZE: Apitegromab during tirzepatide-induced weight loss: Small sponsor-funded phase 2 adult overweight/obesity study, predominantly women. Scans do not isolate all muscle compartments; physical function exploratory. Neither healthy-lifter regimen nor approval for obesity.

Doses people talk about

Amounts circulating online	10 or 20 mg/kg IV per infusion, every four weeks, come from trials rather than verified healthy-lifter regimens.
SMA label context	The saved U.S. label specifies 10 mg/kg every four weeks for its SMA indication; 20 mg/kg is not recommended in that label.

Notes

Circulating amounts come from trials, not established self-use. A peptide wiki lists 20 mg/kg IV every four weeks under a community heading, but identifies SAPPHIRE as its origin. The GLP-1 thread repeats EMBRAZE's 10 mg/kg IV. These are amounts per infusion based on body weight, not daily totals or verified healthy-lifter regimens. Apitegromab community protocols page (Community guide · Accessed 2026-09-30) · EMBRAZE lean-mass result versus flat function endpoint (Community discussion · Accessed 2026-09-30)

SAPPHIRE studied separate 10 and 20 mg/kg IV arms. Ages 2–12 received either amount every four weeks for 12 months; ages 13–21 received 20 mg/kg or placebo. Background treatment was nusinersen or risdiplam. The current SMA label specifies 10 mg/kg per infusion every four weeks; 20 mg/kg is not recommended. SAPPHIRE phase 3 trial: safety and efficacy (Official context · Accessed 2026-09-30) · ISEMBYLD U.S. prescribing information, September 2026 (Official context · Accessed 2026-09-30)

A group difference at week 32 is not a personal effect clock. EMBRAZE used 10 mg/kg IV every four weeks with tirzepatide for 24 weeks. Eight weeks after both treatments stopped, the lean-mass difference was smaller but persisted. That scan result does not establish lasting strength or a washout interval. EMBRAZE: Apitegromab during tirzepatide-induced weight loss (Official context · Accessed 2026-09-30)

Source context — Apitegromab community protocols page: Commercial lead-generation page; no twenty identifiable firsthand accounts inspected. Trial entries are mislabeled as community protocols. Dated availability statements are superseded by September approval; no prevalence, effectiveness or independent user regimen inferred.

Source context — SAPPHIRE phase 3 trial: safety and efficacy: Abstract only, not full text. Sponsor-funded nonambulatory SMA study; pooled doses and separate arms differ. Ages 2–12 primary efficacy population cannot prove healthy-user benefit.

Source context — ISEMBYLD U.S. prescribing information, September 2026: Clinical product/SMA context. Reproductive warnings partly animal-derived, not proven human harm rates. Preparation instructions deliberately excluded. Clinical values remain outside five community quick subjects.

Half-life, onset & duration

Felt onset	The saved accounts do not establish when someone first feels a change after an infusion.
Felt duration	No dependable per-infusion wear-off window is reported; scan results after months do not answer this.
Half-life	24–31 days in an earlier healthy-adult IV study; 31.2 days in the saved SMA label. These measure blood elimination.

Notes

There is no dependable first-dose feeling timeline. The SMA replies express hopes or direct a questioner to a Facebook group; they do not describe a first infusion followed by a measured change. An immediate pump, energy boost, first-week recovery effect or oral onset cannot be inferred from those accounts. How do you think our future will be like? (Community discussion · Accessed 2026-09-30) · Scholar rock: request for trial experiences (Community discussion · Accessed 2026-09-30)

No reliable per-infusion wear-off window is reported. The GLP-1 conversation concerns changes after months of treatment, while the SMA question seeks experiences without receiving a dose-to-offset account. Neither tells a reader how many days an infusion feels active or whether gains persist after stopping. EMBRAZE lean-mass result versus flat function endpoint (Community discussion · Accessed 2026-09-30) · Scholar rock: request for trial experiences (Community discussion · Accessed 2026-09-30)

24–31 days and 31.2 days describe blood elimination. The earlier healthy-adult phase 1 single-IV-dose study, 1–30 mg/kg, reported mean terminal half-lives of 24–31 days. The 2026 label estimates 31.2 days through population modeling in SMA patients. Different populations and analyses produced these values; neither measures felt-benefit duration. Randomized phase 1 study of Apitegromab (2021) (Official context · Accessed 2026-09-30) · ISEMBYLD U.S. prescribing information, September 2026 (Official context · Accessed 2026-09-30)

Source context — Scholar rock: request for trial experiences: No first-person treatment report in visible reply. No private Facebook access; no universal absence claim.

Cycles people discuss

Courses under discussion	The circulating 52-week course describes monitored SMA treatment. The saved record establishes no bodybuilding cycle or useful break length.

Notes

A trial course is not a bodybuilding cycle. The wiki's 52-week entry describes monitored SMA treatment. General weeks-on, weeks-off and cost discussions do not establish an Apitegromab cycle, useful break length or restart rule. Claims about another antibody's three-month run cannot supply that missing schedule. Apitegromab community protocols page (Community guide · Accessed 2026-09-30) · Intro to New Wave of Myostatin Inhibitors (Community discussion · Accessed 2026-09-30)

Source context — Intro to New Wave of Myostatin Inhibitors: Commercial bodybuilding ecosystem. Personal account is a different antibody. Class enthusiasm, cost and assertions of available protocols do not establish Apitegromab access, safety or cycles; sourcing details excluded.

Stacks

SMA treatment	Trials combined apitegromab with nusinersen or risdiplam as disease-specific care.
Tirzepatide	EMBRAZE studied the combination for 24 weeks; this is trial context rather than an established self-use stack.

Notes

Clinical combinations: SMA studies used apitegromab on background SMN-directed treatment, including nusinersen or risdiplam. That is disease-specific combination care, not evidence for a muscle-building peptide stack. [trial]

SMA approval does not approve muscle-building or GLP-1 combinations. The September approval covers adults and children aged two and older with SMA receiving SMN2-targeted treatment. It does not turn online product claims, obesity research or a generic peptide vial into the approved medicine. FDA orphan-drug record: ISEMBYLD approval (Official context · Accessed 2026-09-30)

Source context — FDA orphan-drug record: ISEMBYLD approval: U.S. indication-specific approval, not a bodybuilding or obesity indication and not a certification of products marketed under a research name.

Watch for

Fractures and reactions	The SMA label reports bone fractures, including serious events, and reactions such as respiratory infections, vomiting, headache and hypersensitivity.
Pregnancy and breastfeeding	Human data are inadequate; animal findings underpin fetal-harm and reproductive warnings.
Different drugs and products	A bodybuilding tissue-gain story concerns trevogrumab, not apitegromab. SMA approval does not verify online vials or approve bodybuilding use.

Notes

Bone fractures are a specific labeled risk. The FDA label reports fractures in 9% of the recommended-dose SMA group versus 2% with placebo, including serious events across studies. Low bone density or previous fractures matter. Reported reactions also include respiratory infections, vomiting, cough, headache, stomach illness, sore throat and hypersensitivity. ISEMBYLD U.S. prescribing information, September 2026 (Official context · Accessed 2026-09-30)

Pregnancy, breastfeeding and reproductive effects remain concerns. Human pregnancy and milk data are inadequate; animal findings underpin warnings about fetal harm and reproductive effects. An approved indication does not remove these uncertainties. ISEMBYLD U.S. prescribing information, September 2026 (Official context · Accessed 2026-09-30)

Other myostatin drugs are not interchangeable. A bodybuilding forum lists several antibodies together. Its striking personal account of tissue gain and fat loss is explicitly about REGN-1033, or trevogrumab. That experience, price and course cannot be transferred to Apitegromab. Intro to New Wave of Myostatin Inhibitors (Community discussion · Accessed 2026-09-30)

Full notes

What this muscle antibody actually does

It blocks a muscle-growth brake before it switches on. Myostatin helps limit muscle growth. Apitegromab binds its inactive precursor forms, preventing activation. This is a manufactured antibody protein given through an IV infusion, rather than an oral supplement or a small peptide for daily under-the-skin injections. Official context
Helping muscle is different from repairing lost nerves. In an SMA discussion, a commenter hopes for a small noticeable improvement but worries about longstanding damage. Another distinguishes Apitegromab's muscle target from hoped-for nerve treatments. These are expectations, not reports of recovered abilities after taking it. Reddit · SMA community
Other myostatin drugs are not interchangeable. A bodybuilding forum lists several antibodies together. Its striking personal account of tissue gain and fat loss is explicitly about REGN-1033, or trevogrumab. That experience, price and course cannot be transferred to Apitegromab. Anabolic Steroid Forums

What people hope to gain

Small functional gains can matter in SMA. Patient discussion centers on retaining or improving everyday ability, not gym size. SAPPHIRE found a motor-function advantage for the combined trial doses in younger nonambulatory patients already receiving SMA treatment; the 20 mg/kg arm alone did not meet statistical significance. Reddit · SMA community Official context
Keeping lean tissue during a cut drives the GLP-1 interest. A GLP-1 thread highlights EMBRAZE's 1.9 kg smaller lean-mass loss with tirzepatide plus Apitegromab at 24 weeks. Commenters disagree about the value of a better scan when strength and chair-rise tests showed no notable difference. Lean mass includes more than contractile muscle. Reddit · GLP1ResearchTalk Official context

Doses people discuss

Circulating amounts come from trials, not established self-use. A peptide wiki lists 20 mg/kg IV every four weeks under a community heading, but identifies SAPPHIRE as its origin. The GLP-1 thread repeats EMBRAZE's 10 mg/kg IV. These are amounts per infusion based on body weight, not daily totals or verified healthy-lifter regimens. Community guide Reddit · GLP1ResearchTalk

Half-life

No community-measured half-life is established here. The public trial-experience request contains no participant's drug-level measurements. A monthly infusion schedule is not a half-life measurement; neither is a report of feeling stronger. Formal blood-level estimates are listed separately below. Reddit · SMA community Community guide

When effects might start

There is no dependable first-dose feeling timeline. The SMA replies express hopes or direct a questioner to a Facebook group; they do not describe a first infusion followed by a measured change. An immediate pump, energy boost, first-week recovery effect or oral onset cannot be inferred from those accounts. Reddit · SMA community Reddit · SMA community

How long benefits might last

No reliable per-infusion wear-off window is reported. The GLP-1 conversation concerns changes after months of treatment, while the SMA question seeks experiences without receiving a dose-to-offset account. Neither tells a reader how many days an infusion feels active or whether gains persist after stopping. Reddit · GLP1ResearchTalk Reddit · SMA community

Cycles and treatment courses

A trial course is not a bodybuilding cycle. The wiki's 52-week entry describes monitored SMA treatment. General weeks-on, weeks-off and cost discussions do not establish an Apitegromab cycle, useful break length or restart rule. Claims about another antibody's three-month run cannot supply that missing schedule. Community guide Community Anabolic Steroid Forums

Clinical numbers behind the discussion

SAPPHIRE studied separate 10 and 20 mg/kg IV arms. Ages 2–12 received either amount every four weeks for 12 months; ages 13–21 received 20 mg/kg or placebo. Background treatment was nusinersen or risdiplam. The current SMA label specifies 10 mg/kg per infusion every four weeks; 20 mg/kg is not recommended. Official context Official context
24–31 days and 31.2 days describe blood elimination. The earlier healthy-adult phase 1 single-IV-dose study, 1–30 mg/kg, reported mean terminal half-lives of 24–31 days. The 2026 label estimates 31.2 days through population modeling in SMA patients. Different populations and analyses produced these values; neither measures felt-benefit duration. Official context Official context
A group difference at week 32 is not a personal effect clock. EMBRAZE used 10 mg/kg IV every four weeks with tirzepatide for 24 weeks. Eight weeks after both treatments stopped, the lean-mass difference was smaller but persisted. That scan result does not establish lasting strength or a washout interval. Official context

What needs caution

Bone fractures are a specific labeled risk. The FDA label reports fractures in 9% of the recommended-dose SMA group versus 2% with placebo, including serious events across studies. Low bone density or previous fractures matter. Reported reactions also include respiratory infections, vomiting, cough, headache, stomach illness, sore throat and hypersensitivity. Official context
Pregnancy, breastfeeding and reproductive effects remain concerns. Human pregnancy and milk data are inadequate; animal findings underpin warnings about fetal harm and reproductive effects. An approved indication does not remove these uncertainties. Official context
Steroid stack rules do not establish antibody safety. Suppression, cholesterol and post-cycle therapy chatter belongs to other hormonal agents, not a demonstrated Apitegromab profile. Multi-agent side-effect logs are difficult to interpret; long-term healthy-user and unverified-product risks remain uncertain. Severe allergic symptoms, chest pain, new neurological symptoms or uncontrolled blood pressure or glucose need medical care. Community
SMA approval does not approve muscle-building or GLP-1 combinations. The September approval covers adults and children aged two and older with SMA receiving SMN2-targeted treatment. It does not turn online product claims, obesity research or a generic peptide vial into the approved medicine. Official context

What the community debate adds

A better scan and better performance are different goals. In the GLP-1 discussion, one commenter values retained tissue for appearance and metabolism; others want evidence of usable strength. The proposed metabolic benefits are opinions, not outcomes that thread establishes. This distinction explains why the same result excites some readers and leaves others unconvinced. Reddit · GLP1ResearchTalk
Protein and lifting are not equally easy for everyone. A BodyHackGuide commenter says appetite suppression makes enough protein very difficult. Another reports maintained or increased lifts on tirzepatide, while a separate commenter describes losing 10 kg over four months with scans showing muscle maintenance rather than growth. None reports taking Apitegromab; their disagreement explains interest in a muscle-preserving add-on. Reddit · BodyHackGuide
One training success is not proof that everyone can avoid loss. A tirzepatide-using blogger describes adding lean mass while losing fat through diet and coached training, without Apitegromab. This illustrates the alternatives people compare, not evidence of this antibody's effectiveness. Diet, programming and other compounds also complicate before-and-after claims. Personal report Community
Bodybuilding enthusiasm comes with substantial speculation. A moreplatesmoredates thread jumps from Apitegromab research to claims about enormous hearts, weaker muscle and necessary steroid stacks. Those replies are opinions without Apitegromab treatment measurements. Class-wide fears and dramatic growth promises should not be presented as observed side effects or benefits of this particular antibody. Reddit · moreplatesmoredates
Patient hopes are not trial-participant testimonials. The SMA future discussion hopes for modest improvement despite irreversible changes. A different thread asks participants how treatment is going, but its visible respondent is not in the trial and suggests Facebook. These public accounts do not establish positive, unchanged or adverse firsthand Apitegromab experiences. Reddit · SMA community Reddit · SMA community